{"id":"gsk-bio-s-influenza-vaccine-gsk2186877a","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Systemic reactions (fever, myalgia, fatigue)"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This vaccine candidate uses recombinant technology to present influenza antigens in a way intended to broaden and enhance immune recognition across multiple influenza strains. The specific mechanism leverages GSK's vaccine platform technology to improve upon traditional seasonal influenza vaccines by potentially offering improved immunogenicity or broader strain coverage.","oneSentence":"GSK2186877A is a recombinant influenza vaccine designed to stimulate immune responses against influenza virus through a novel antigenic approach.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:39.875Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention (seasonal influenza)"}]},"trialDetails":[{"nctId":"NCT00992784","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-15","conditions":"Influenza","enrollment":370},{"nctId":"NCT00938392","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07-30","conditions":"Influenza","enrollment":726},{"nctId":"NCT00760617","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-06","conditions":"Influenza","enrollment":526},{"nctId":"NCT00753272","phase":"PHASE3","title":"Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-15","conditions":"Influenza","enrollment":43695}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK Bio's influenza vaccine GSK2186877A","genericName":"GSK Bio's influenza vaccine GSK2186877A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK2186877A is a recombinant influenza vaccine designed to stimulate immune responses against influenza virus through a novel antigenic approach. Used for Influenza prevention (seasonal influenza).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}